Accumulated studies have demonstrated that E2F1 can mediate the EMT process in various cancers, including non-small cell lung carcinoma [41], ovarian cancer [42], clear cell renal cell carcinoma [43], and BC [44]. This evidence concerns the gene E2F1 and ovarian carcinoma.